Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Tabrecta capmatinib Metastatic non-small cell lung cancer (NSCLC) Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Tafinlar Dabrafenib Metastatic Melanoma Reimburse with clinical criteria and/or conditions Complete
Tafinlar & Mekinist in combo Dabrafenib & Trametinib in combo Non-Small Cell Lung Cancer Do not reimburse Complete
Tafinlar & Mekinist in combo Dabrafenib & Trametinib in combo Melanoma Adjuvant Therapy Reimburse with clinical criteria and/or conditions Complete
Tafinlar & Mekinist in combo Dabrafenib & Trametinib in combo Metastatic Melanoma Reimburse with clinical criteria and/or conditions Complete
Tafinlar and Mekinist Dabrafenib and Trametinib NSCLC BRAF V600 Reimburse with clinical criteria and/or conditions Complete
Tafinlar and Mekinist dabrafenib and trametinib Pediatric high-grade glioma with BRAF V600E Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Tafinlar and Mekinist dabrafenib and trametinib Pediatric low-grade glioma with BRAF V600E Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Tafinlar-Mekinist dabrafenib trametinib Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation Cancelled
Tagrisso Osimertinib Non-Small Cell Lung Cancer (NSCLC) (first line) Reimburse with clinical criteria and/or conditions Complete